monoclonal antibodies

VUMC joins effort to stop spread of two deadly viruses

Researchers at Vanderbilt University Medical Center are participating in a national effort to develop vaccines and other treatments as countermeasures to prevent the spread of two emerging and deadly viruses — Nipah and Hendra.

Grant supports novel imaging initiative to enhance cancer care

A Vanderbilt initiative to develop predictive imaging technologies that clinicians can use to better match patients with personalized care has received National Cancer Institute (NCI) funding.

Research assistant Mahsa Majedi loads reagent used in DNA sample preparation in the genomics lab. She is part of a team of more than a dozen people at VUMC who are “sprinting” to develop — within 90 days — an antibody-based treatment to stop the spread of the Zika virus.

VUMC scientists ‘sprint’ to find anti-Zika antibodies

Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

2018 a year of growth, achievement for VUMC

The following is a roundup of the news that made headlines at Vanderbilt University Medical Center in 2018.

Discovery could lead to neutralizing West Nile virus

Researchers at Vanderbilt University Medical Center and colleagues have isolated a human monoclonal antibody that can “neutralize” the West Nile virus and potentially prevent a leading cause of viral encephalitis (brain inflammation) in the United States.

Link between immune system, disease explored

The first Flexner Discovery Lecture of the academic year featured presentations by two Vanderbilt faculty members.

1 4 5 6 7 8 9